Constitution Medical, Inc. (CMI), headquartered in Boston, Massachusetts, is an early-stage developer of novel blood diagnostic technologies. The company is developing Bloodhound, an innovative hematology platform focused on Complete Blood Count (CBC), the most commonly ordered laboratory test today and a $2 billion worldwide market. Bloodhound is a fully automated analyzer that digitally counts cells and cell types. Compared to today’s systems, Bloodhound is more reliable, accurate, and convenient to use, and also takes less space in the lab. CMI is currently completing product development of Bloodhound and expects to initiate clinical trials in 2013.
CMI was formed in June 2008 by Warburg Pincus and senior healthcare executives Patrick J. Sullivan and Daniel J. Levangie. Mr. Sullivan is the former President and Chief Executive Officer of Cytyc Corporation and, until recently, served as Executive Chairman of Hologic, Inc., which acquired Cytyc in October 2007. Mr. Levangie previously was Executive Vice President of Cytyc and President of Cytyc’s Surgical Products Division. Over the course of 15 years at Cytyc, one of the leading companies focused on improving healthcare for women, the CMI executive team helped grow the company to $700 million in annual revenues and establish operations in 20 countries.
In February 2009, Warburg Pincus backed CMI to acquire the Bloodhound technology and has continued to provide growth capital and strategic support to drive the development and commercialization of the system.
Back to Previous Page